Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00274222
Status:
TERMINATED
Last Update Posted:
2006-01-10
First Post:
2006-01-09
Brief Title:
The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD
Sponsor:
Inonu University
Organization:
Inonu University
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2006-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to evaluate the hypothesis that nebulized budesonide might be an alternative to systemic corticosteroids SC in the treatment of patients with acute exacerbations of COPD AECOPD
Detailed Description:
Patients hospitalized with AECOPD were randomized into three groups Group I received only bronchodilator treatment BDT Group II received SC 40 mg prednisolon plus BDT and Group III received nebulized budesonide NB1500 mcg qid plus BDT Improvement rates in multiple parameters during 10-day hospitalization and acute exacerbation and re-hospitalization rates within one-month after discharge were compared between the groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None